Ampicillin Market Is Expected To Reach A Revenue Of USD 480.1 Mn By 2033, At 2.4% CAGR: Insights by Dimension Market Research
May 21, 2024 13:49 ET
|
Dimension Market Research
New York, May 21, 2024 (GLOBE NEWSWIRE) -- Overview The Global Ampicillin Market size is expected to reach USD 388.1 million by 2024 and is further anticipated to reach USD 480.1 million by...
Antibiotic Resistance Market Projected to Hit US$ 17.8 Billion by 2033 with a CAGR of 5.3% | Persistence Market Research
January 12, 2024 04:08 ET
|
Persistence Market Research
New York, Jan. 12, 2024 (GLOBE NEWSWIRE) -- The growing demand for new antibiotic therapies to combat antibiotic resistance is a prominent driver in the global market. In a July 2023 Science Daily...
Mushrooms Inc (OTC:MSRM) Announces Full Patent Filing for Groundbreaking Mycelium Technology Providing Bacterial Detection and Nutrient Delivery
October 18, 2023 08:00 ET
|
Mushrooms Inc.
ESTERO, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- via IBN -- Mushrooms Inc., (OTC: MSRM) a leader in mycelium research and development, proudly announces the successful filing of its non-provisional...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2020 16:45 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update
March 16, 2020 08:45 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at March Investor Conferences
February 26, 2020 16:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
January 13, 2020 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
December 04, 2019 16:01 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review
November 04, 2019 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2019 17:08 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...